🇨đź‡Â·8h agoIndustry
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
Publisher
R
Roche Newsroom
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Roche Newsroom
- Region
- Switzerland
- Scope
- Industry
- Published
- July 15, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on roche.com
Leave the platform to read the original full article on the publisher site.
Source: Roche Newsroom
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News/2h ago
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
Merck & Co. (MSD) News/2h ago
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
Hyman, Phelps & McNamara (FDA Law)/7h ago
Senate and House Lawmakers Unveil Competing 340B Reform Proposals
Sumitomo Pharma/8h ago